공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

오피오이드 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Opioids Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 659352
페이지 정보 영문
가격
US $ 4,250 ₩ 4,793,000 PDF (Single User License)
US $ 4,750 ₩ 5,357,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,766,000 PDF (Site License)
US $ 7,500 ₩ 8,458,000 PDF (Corporate License)


오피오이드 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Opioids Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 오피오이드(Opioids) 시장을 조사했으며, 전체적인 시장 동향, 제품 및 지역별 동향, 시장 성장 영향요인, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 추론

제5장 시장 개요

  • 현재의 시장 시나리오
  • Porter's Five Forces 분석
    • 공급업체의 협상력
    • 소비자의 협상력
    • 신규 진출기업의 위협
    • 대체 제품 및 서비스의 위협
    • 업계 내 경쟁

제6장 성장 촉진요인 및 저해요인, 기회, 과제 분석(DROC)

  • 시장 성장 촉진요인
    • 정형외과적 질환 및 만성통증의 유행
    • 오피오이드 즉시 방출에서 지속 방출성 제제로
    • 제네릭 의약품 제조업체의 남용억제제형(ADF: abuse-deterrent)에 대한 관심 증대
    • 증가하는 완화치료 시설
  • 시장 성장 저해요인
    • 오피오이드 대체품으로서의 대마 출현과 합법화
    • 처방약 남용
  • 시장 기회
  • 주요 과제

제7장 시장 세분화

  • 제품 종류별
    • 코데인(Codeine)
    • 펜타닐(Fentanyl)
    • 모르핀(Morphine)
    • 메페리딘(Meperidine)
    • 메타돈(Methadone)
    • 기타
  • 수용체 결합별
    • Strong Agonist
    • Mild to Moderate Agonist
    • 혼합 수용체 반응
  • 용도별
    • 통증관리
    • 감기와 기침
    • 설사
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제8장 경쟁 구도

  • 기업 인수합병(M&A) 분석
  • 합의, 협력, 제휴
  • 신제품 발매

제9장 주요 기업

  • Allergan
  • Egalet Corporation
  • Endo Pharmaceuticals Inc.
  • Janssen Pharmaceuticals Inc.
  • Mallinckrodt
  • Pfizer Inc.
  • Purdue Pharma LP
  • Qrxpharma Limited
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

제10장 시장 전망

LSH 18.07.17

The Global Opioids Market was valued at approximately USD 19,869 million in 2020, and it is expected to reach USD 24,435 million in 2026 with a CAGR of 3.5% over the forecast period.

Globally, the COVID-19 pandemic showed many negative effects across the medical spectrum which include a decrease in face-to-face appointments and an increase in telehealth visits. The COVID-19 pandemic has also resulted in a period of isolation, to maintain sufficient capacity in hospitals and to reduce the spread of the virus. Adding to that the chronic pain was one of the hardest-hit field from the COVID-19 pandemic leaving many patients overburdened with their chronic pain and their on-going treatment delayed. For instance, according to a research article by Rajendra K Sahoo et a., published in Indian Journal of Anesthesia 2020, the study results found that 63.16% of pain physicians had the fear of spreading or contracting disease to patient family members, 26.79% had impaired sleep, 1.43% physicians were feeling depressed and 8.14% had feelings of anxiety.

Some of the other major factors driving the market growth include the increasing prevalence of diseases that cause chronic pain, such as cancer, arthritis, lower back pain, fibromyalgia and postsurgical pain, inclination toward extended release formulations from immediate release of opioids and rising focus on abuse-deterrent formulation (ADF) by generic manufacturers.

Opioids are considered as most effective drugs for the management of pain. Moreover, their use in the management of chronic pain is considered to be standard practice in most parts of the world. Due to an increase in the burden of medical ailments, the Opioids market is expected to grow over the forecast period.

Furthermore, opioids play a key role in post-operative settings to provide adequate analgesia. As per the Center for Disease Control and Prevention 2020, over 32.5 million patients were affected by osteoarthritis in the United States. In United Kingdom, there is a steady increasing rate of osteoarthritis. As per Versus Arthritis, in 2019, it was estimated that over 18% of people who were above 45 year of age in England had osteoarthritis of the knee.

According to a research article by Eugenio Cavalli et a., published in International Journal of Immunopathology and Pharmacology 2019, globally, the prevalence of neuropathic pain among general population was estimated to be between 3%-17%. Therefore, opioid therapy is the mainstay of orthopedic treatment of patients with moderate to severe pain, and this helps to drives the overall growth of the market. However, factors such as advent and legalization of cannabis as an alternative to opioids and prescription drug abuse is expected to impede market growth over the forecast period.

Key Market Trends

Strong Agonists are Expected to Hold Significant Market Share in the Receptor Binding Segment

An agonist is a drug molecule that triggers certain receptors in the brain. This agonist produces significant physiological/pharmacological response when only a relatively small number of receptors are occupied, i.e. the drug has high intrinsic activity. Some of the strong agonist opioids include Fentanyl, morphine, dihydromorphinone, meperidine, oxycodone, and oxymorphone.

Globally, COVID-19 has created a health crisis. During the COVID-19 pandemic, globally, health agencies were engaged in the prevention of infection and providing services to COVID-19 patients. This has led to the cancellation of elective surgeries, elective consultations which showed effect on pain services by hospitals and pain clinics.

Methadone is a strong agonist which is found to be an effective treatment for addiction to opioid drugs (such as heroin). Strong agonist bind tightly to opioid receptors which undergo significant conformational changes.

Globally, there are many people who experience pain in their daily lives. For instance, as per Chronic Pain Association of Canada (CPAC) 2019 report, estimates that chronic pain patients were experiencing a decline quality of life with increasing pain. Moreover, between 17-31% of people report chronic pain. 50% percent of hospitalized patients report acute pain of moderate to severe intensity. It was estimated that annual direct medical costs for chronic pain management found to be between USD 10,000-14,000 per patient.

The market players are adopting various strategies such as product approvals and developments to expand their product portfolio, expansions, collaborations and mergers to increase market share. For instance, in November 2018, AcelRx Pharmaceuticals, Inc. received US FDA approval for DSUVIA (Dsuvia is a opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 times as potent as morphine) for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opioid analgesic. Thus, owing to above mentioned factors it is expected to drive the segment growth in near future.

North America Dominates the Market and is Expected to Continue to Dominate in the Forecast Period

The major factors driving the market growth in North America region include rising incidence of orthopedic diseases, growing prevalence of chronic diseases such as cancer and diabetes and rise in disposable income and surge in geriatric population along with presence of key market players in the region.

In United States, the COVID-19 pandemic forced healthcare systems to redistribute healthcare resources towards COVID-19 dedicated sites and intensive care units. During the COVID-19 pandemic 2020, chronic pain services which were non-urgent, outpatient and elective interventional procedures have been reduced or interrupted during the COVID-19 pandemic in order to reduce the risk of viral spread.

According to a research article by Filomena Puntillo et al., published in Best Practice and Research: Clinical Anesthesiology Journal 2020, Chronic pain populations remain isolated with consequent social and psychological impact. The shutdown of pain services due to lockdown imposed by United States government during the COVID-19 pandemic has affected chronic pain management.

The population of cancer survivors in the United States is growing rapidly with increasing cancer pain patients which is boosting the market growth. For instance, according to a research article by Changchuan Jiang et al., published in JAMA Oncology Journal 2019, as per study results, among 4,526 cancer survivors, 1,648 subjects reported to have chronic pain and 768 subjects to have high-impact chronic pain (HICP), representing approximately 5.39 million and 2.51 million cancer survivors, respectively.

In addition, as per government of Canada, in Canada, in 2019, around 7.63 million people had chronic pain. In Canada, Chronic pain had significant impacts on mental and physical health, family and community life, and the economy, with the total direct and indirect cost of USD 38.3 to USD 40.4 billion in 2019.

Morphine and Codeine are the most commonly prescribed opioids for cancer pain. In 2018, the United States Food and Drug Administration launched the 2018 Strategic Policy Roadmap, which aims at reducing the misuse and abuse of opioid drugs. Thus, owing to above mentioned factors it is expected to show significant market growth over the forecast period.

Competitive Landscape

The Opioids Market is fragmented competitive. The market consists of several players. However, with the rising usage of opioids in medicines, more companies are trying to enter this market, especially in the emerging markets. However, strict laws and stringent regulatory policies are deterring market penetration by small- and mid-sized companies. Sone of the market players include Teva Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals PLC, Purdue Pharmaceuticals L.P. and others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain
    • 4.2.2 Inclination toward Extended Release Formulations from Immediate Release of Opioids
    • 4.2.3 Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers
  • 4.3 Market Restraints
    • 4.3.1 Advent and Legalization of Cannabis as an Alternative to Opioids
    • 4.3.2 Prescription Drug Abuse
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Codeine
    • 5.1.2 Fentanyl
    • 5.1.3 Morphine
    • 5.1.4 Meperidine
    • 5.1.5 Methadone
    • 5.1.6 Other Product Types
  • 5.2 By Receptor Binding
    • 5.2.1 Strong Agonist
    • 5.2.2 Mild to Moderate Agonist
  • 5.3 By Application
    • 5.3.1 Pain Management
      • 5.3.1.1 Cancer Pain
      • 5.3.1.2 Neuropathic Pain
      • 5.3.1.3 Osteoarthritis Pain
      • 5.3.1.4 Other Pain Managements
    • 5.3.2 Cold and Cough
    • 5.3.3 Diarrhoea
    • 5.3.4 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States (By Product Type, By Receptor Binding and By Application)
      • 5.4.1.2 Canada (By Product Type, By Receptor Binding and By Application)
      • 5.4.1.3 Mexico (By Product Type, By Receptor Binding and By Application)
    • 5.4.2 Europe
      • 5.4.2.1 Germany (By Product Type, By Receptor Binding and By Application)
      • 5.4.2.2 United Kingdom (By Product Type, By Receptor Binding and By Application)
      • 5.4.2.3 France (By Product Type, By Receptor Binding and By Application)
      • 5.4.2.4 Italy (By Product Type, By Receptor Binding and By Application)
      • 5.4.2.5 Spain (By Product Type, By Receptor Binding and By Application)
      • 5.4.2.6 Rest of Europe (By Product Type, By Receptor Binding and By Application)
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China (By Product Type, By Receptor Binding and By Application)
      • 5.4.3.2 Japan (By Product Type, By Receptor Binding and By Application)
      • 5.4.3.3 India (By Product Type, By Receptor Binding and By Application)
      • 5.4.3.4 Australia (By Product Type, By Receptor Binding and By Application)
      • 5.4.3.5 South Korea (By Product Type, By Receptor Binding and By Application)
      • 5.4.3.6 Rest of Asia-Pacific (By Product Type, By Receptor Binding and By Application)
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC (By Product Type, By Receptor Binding and By Application)
      • 5.4.4.2 South Africa (By Product Type, By Receptor Binding and By Application)
      • 5.4.4.3 Rest of Middle East and Africa (By Product Type, By Receptor Binding and By Application)
    • 5.4.5 South America
      • 5.4.5.1 Brazil (By Product Type, By Receptor Binding and By Application)
      • 5.4.5.2 Argentina (By Product Type, By Receptor Binding and By Application)
      • 5.4.5.3 Rest of South America (By Product Type, By Receptor Binding and By Application)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mallinckrodt Pharmaceuticals LLC
    • 6.1.2 Purdue Pharmaceuticals L.P.
    • 6.1.3 Rhodes Technologies LP
    • 6.1.4 Sun Pharmaceutical Industries Ltd
    • 6.1.5 Teva Pharmaceuticals Inc.
    • 6.1.6 Vertice Pharma LLC
    • 6.1.7 Johnson and Johnson
    • 6.1.8 AbbVie Inc (Allergan PLC)
    • 6.1.9 Hikma Pharmaceuticals PLC
    • 6.1.10 Endo Pharmaceuticals Inc.
    • 6.1.11 Zyla Life Sciences (Egalet Corporation)
    • 6.1.12 Amneal Pharmaceuticals Inc.
    • 6.1.13 Pfizer Inc
    • 6.1.14 AcelRx Pharmaceuticals, Inc
    • 6.1.15 Archimedes Pharma
    • 6.1.16 Cadila Healthcare (Sentynl Therapeutics, Inc.)
    • 6.1.17 Alcaliber S.A.
    • 6.1.18 Verve Health Care LTD.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q